- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00861809
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
January 27, 2017 updated by: GlaxoSmithKline
A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Controlled Type 1 Diabetes Mellitus (glucose < 250 mg/dL) with onset < 30 years of age.
- Male or female between 18 and 70 years of age, inclusive.
- Patient has documented diagnosis of moderate to severe gastroparesis (> 30% at 2 h as determined by scintigraphy; or t1/2b > 109 min as determined by 13C-octanoic acid breath test). All of the following apply:
- Confirmed delayed gastric emptying (properly conducted gastric emptying assessments within last 6 months acceptable) AND a minimum 3 month history of relevant symptoms for gastroparesis (e.g., chronic postprandial fullness, postprandial nausea, vomiting)
- A female patient is eligible to participate if she is of:
- Non-childbearing potential
- Child-bearing potential and agrees to use contraception for at least 4 days following the last dose of study medication.
- Male patients must agree to use contraception from the time of the first dose of study medication through at least 4 days after the last dose of study medication.
- Body weight ≤110 kg and BMI < 32.0 kg/m2 (inclusive).
- Patient has never had a gastrectomy, nor major gastric surgical procedure or any evidence of bowel obstruction within the previous 12 months
- Dosage of any concomitant medications has been stable for at least 3 weeks, except for routine adjustments in daily insulin treatments
- HbA1c level is ≤ 10.0%
- Calculated creatinine clearance > or equal to 50 ml/min
- QTcB or QTcF < 450 msec or QTc<480msec in patients with Bundle Branch Block based on single or average QTc value of triplicate values obtained over a brief recording period.
- AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion Criteria:
- Patient has acute severe gastroenteritis
- Patient has a gastric pacemaker
- Patient is on chronic parenteral feeding
- Patient has daily persistent severe vomiting
- Patient has pronounced dehydration
- Patient has had clinical diabetic ketoacidosis in last 4 weeks
- Patient has a history of eating disorders (anorexia nervosa, binge eating, bulimia)
- Use of medications potentially influencing upper gastrointestinal motility or appetite within one week of the study (e.g., prokinetic drugs, macrolide antibiotics (erythromycin))
- Patient is taking opiates.
- Use of prohibited medications listed in Section 9.2 within the restricted timeframe relative to the first dose of study medication.
- History or presence of clinically significant gastro-intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
- Presence of thyroid dysfunction (NOTE: patients with abnormal TSH at screening/baseline are not eligible. Patients with a history of hypothyroidism on a stable dose of thyroid replacement therapy are eligible to participate in the study).
- The patient has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum or urine hCG test (from the first urine of the day) at screening or prior to dosing.
- Lactating or pregnant females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Patients deemed unable to comply with the procedures outlined in the protocol may be excluded at the Investigator's discretion.
- For male volunteers: An unwillingness of the male patient to comply with the contraception requirements listed in Section 8.1, from the time of the first dose of study medication until at least 4 days following administration of the last dose of study medication.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 Period 1
All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
|
25 mg
placebo comparator
50 mg
125 mg
|
Experimental: Cohort 1 Period 2
All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
|
25 mg
placebo comparator
50 mg
125 mg
|
Experimental: Cohort 1 Period 3
All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
|
25 mg
placebo comparator
50 mg
125 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Gastric emptying, as measured by the 13C octanoic acid breath test (Gastric half emptying time (t1/2b), Duration of the lag time (tlag), Gastric evacuation coefficient (GEC))
Time Frame: 1.5 h post dose to 5.5 h post dose
|
1.5 h post dose to 5.5 h post dose
|
Safety and tolerability of GSK962040 (Change from baseline and number of patients outside the normal range for blood pressure, heart rate, 12-lead ECG parameters)
Time Frame: 2 h post dose
|
2 h post dose
|
Pharmacokinetic parameters of GSK962040: Cmax, Tmax, AUC(0-t), AUC(0-inf) for single-dose, CL/F, V/F, and, if possible, half-life
Time Frame: 24 h post dose
|
24 h post dose
|
Safety and tolerability of GSK962040 (Adverse events)
Time Frame: 6 weeks
|
6 weeks
|
Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters)
Time Frame: 24 h post dose
|
24 h post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bowel movement parameters (Time to first bowel movement after first dose, Bowel movement count, Stool consistency (Bristol Stool Form scale))
Time Frame: 24 h post dose
|
24 h post dose
|
PK/PD relationship of PP, plasma glucagon, GLP-1, and ghrelin after a single dose of GSK962040.
Time Frame: 0-6 h post dose
|
0-6 h post dose
|
Plasma glucose
Time Frame: 24 h post dose
|
24 h post dose
|
Food intake
Time Frame: 24 h post dose
|
24 h post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
November 1, 2010
Study Completion (Actual)
November 1, 2010
Study Registration Dates
First Submitted
February 26, 2009
First Submitted That Met QC Criteria
March 12, 2009
First Posted (Estimate)
March 13, 2009
Study Record Updates
Last Update Posted (Estimate)
January 30, 2017
Last Update Submitted That Met QC Criteria
January 27, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 111809
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Study Protocol
Information identifier: 111809Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 111809Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 111809Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 111809Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 111809Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 111809Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 111809Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroparesis
-
Johns Hopkins UniversityCompletedDiabetic Gastroparesis | Idiopathic Gastroparesis | Gastroparesis PostoperativeUnited States
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroparesis | Diabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Vanda PharmaceuticalsRecruitingGastroparesis | Diabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Neurogastrx, Inc.CompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Texas Tech University Health Sciences Center, El...CompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
TakedaCompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsActive, not recruitingGastroparesis | Diabetic Gastroparesis | Idiopathic GastroparesisUnited States
-
Millennium Pharmaceuticals, Inc.CompletedDiabetic Gastroparesis | Idiopathic GastroparesisUnited States, Belgium, Japan, Poland
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling by invitationFunctional Dyspepsia | Diabetics Without Symptoms of Gastroparesis | Diabetic Gastroparesis | Idiopathic Gastroparesis | Total or Partial Gastrectomy | Chronic NauseaUnited States
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruiting
Clinical Trials on GSK962040 25 mg
-
GlaxoSmithKlineCompletedGastroparesisUnited States, Australia, Belgium, United Kingdom, Canada, Sweden
-
GlaxoSmithKlineCompletedGastroparesisGermany, Australia, Sweden, United Kingdom
-
GlaxoSmithKlineCompletedGastroparesisAustralia
-
Zydus Lifesciences LimitedRecruitingAmyotrophic Lateral SclerosisIndia
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompletedInfection, Human Immunodeficiency VirusUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Idorsia Pharmaceuticals Ltd.CompletedHepatic ImpairmentSwitzerland
-
Idorsia Pharmaceuticals Ltd.Completed
-
Repros Therapeutics Inc.Completed